Jeffrey J. Tosoian, MD, MPH, presents “MyProstateScore 2.0 (MPS2): A Novel, Noninvasive Urine Test Prior to Prostate Biopsy.”
How to cite: Tosoian, Jeffrey J. “MyProstateScore 2.0 (MPS2): A Novel, Noninvasive Urine Test Prior to Prostate Biopsy.” May 27, 2025. Accessed Jun 2025. https://grandroundsinurology.com/myprostatescore-2-0-mps2-a-novel-noninvasive-urine-test-prior-to-prostate-biopsy/
MyProstateScore 2.0 (MPS2): A Novel, Noninvasive Urine Test Prior to Prostate Biopsy – Summary
Jeffrey J. Tosoian, MD, MPH, Assistant Professor and Director of Translational Cancer Research, Vanderbilt University, Nashville, Tennessee, introduces the MyProstateScore 2.0 (MPS2) test as a novel, noninvasive urine-based diagnostic tool. In this 11-minute presentation, he shares that the test helps determine whether to proceed with an MRI or biopsy. Developed through a collaboration of academic centers and validated independently at Fred Hutchinson Cancer Center, MPS2 focuses on detecting clinically significant (Grade Group 2–5) prostate cancers.
The test evolved by identifying cancer-specific genetic markers, particularly those overexpressed in higher-grade disease, from a pool of nearly 60,000 candidates. Of these, 18 biomarkers were selected and shown to perform well in urine-based detection. MPS2 includes high-specificity markers such as the T2:ERG fusion transcript and four unique to high-grade cancers, surpassing prior biomarker panels in scope and accuracy.
In blinded validation studies, MPS2 demonstrated the ability to avoid 35–42% of avoidable biopsies or MRIs in biopsy-naïve patients, and 44–53% in those with a prior negative biopsy. This reflects a significant improvement over older tools. Since MPS2 relies minimally on PSA, which is unreliable in the repeat biopsy setting. Its sensitivity and negative predictive value for Grade Group 3+ cancers reached 99%.
Using first-catch urine samples, MPS2 performs effectively without requiring a digital rectal exam. Even without incorporating clinical variables, the biomarkers alone offer strong performance. Compared to the PCPT risk calculator, MPS2 increases the percentage of avoidable procedures by 15–40%.
Dr. Tosoian encourages clinicians to adopt the test, emphasizing that it is simple to order via the Lynx Dx portal, results are returned in under a week, and the test is broadly reimbursed. Its user-friendly risk report enhances patient discussions, and its home collection option integrates well with in-person and virtual care.
